Arix to Present at Mello Investment Trusts &amp...

Arix Bioscience PLC (ARIX) Arix to Present at Mello Investment Trusts & Funds 06-Dec-2022 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience plc Arix to Present at Mello Investment Trusts & Funds LONDON, 6 December 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces that the Company will be presenting at the Mello Investment Trusts & Funds virtual webinar, taking place between 2pm and 5pm on Tuesday 13 December 2022. Robert Lyne, CEO, will provide a live update and Q&A session on the Company, its investment strategy and outlook, at 2.30pm on the day. The presentation will be hosted online and is open to all existing and potential shareholders. Individuals wishing to attend can register via the below link: https://melloevents.com/mello-investment-trusts-and-funds/ [ENDS] Enquiries For more information on Arix, please contact: Arix Bioscience plc [phone] [e-mail] Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson [phone] [e-mail] About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

ISIN:	GB00BD045071
Category Code:	MSCL
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	206324
EQS News ID:	1505503

End of Announcement	EQS News Service